Cadrenal Therapeutics, Inc. Common Stock (CVKD) Sentiment Analysis

Cadrenal Therapeutics, Inc. Common Stock (CVKD) has an ST Score of 40.9 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate CVKD a Buy, with a price target of $32.00 (+2976.9% vs the current price). Our ST Score grades it C (40.9/100). The ST Score is a data-driven signal, not a recommendation.

Valuation B-, Profitability F, Financial Strength B-, Momentum F, Growth B+, Forecast A.

Cadrenal Therapeutics, Inc. Common Stock (CVKD) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Cadrenal Therapeutics, Inc. Common Stock (CVKD) earns a growth grade of B+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Cadrenal Therapeutics, Inc. Common Stock (CVKD) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Cadrenal Therapeutics, Inc. Common Stock (CVKD) earns a financial strength grade of B-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Cadrenal Therapeutics, Inc. Common Stock (CVKD) is $32.00 from 1 analysts, which is +2976.9% versus the recent price of $1.04.

Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.